Government-Use License and Stem Cell-Based Pharmaceuticals Patent: Equitable Access to Covid-19 Medications
Fuente:
Redalyc
Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Universidad del Zulia
2020
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1876443386515292160 |
|---|---|
| author | Mas RAHMAH |
| author_facet | Mas RAHMAH |
| contents | Government-Use License and Stem Cell-Based Pharmaceuticals Patent: Equitable Access to Covid-19 Medications Mas RAHMAH Política 19 Covid drugs patent Indonesia In response to the outbreak of the Covid-19 pandemic, some pharmaceutical companies have patented their drugs to combat it, including those based on stem cells. Questions about how to access such drugs will likely be raised because patent protection grants an exclusive right to the patent owner, to prevent someone else from benefiting from a large-scale price increase. The document will then review the regulation and practice of government use in Indonesia and the possibility of such a mechanism to access Covid-19 drugs. 2020 artículo científico 1316-5216 https://www.redalyc.org/articulo.oa?id=27964362009 https://www.redalyc.org/journal/279/27964362009/ https://www.redalyc.org/journal/279/27964362009/html/ https://www.redalyc.org/journal/279/27964362009/27964362009.epub https://www.redalyc.org/journal/279/27964362009/movil https://doi.org/10.5281/zenodo.4009611 en http://www.redalyc.org/revista.oa?id=279 Utopía y Praxis Latinoamericana application/pdf Universidad del Zulia Utopía y Praxis Latinoamericana (República Bolivariana de Venezuela) Num.7 Vol.25 |
| format | Artículo científico |
| id | redalyc_27964362009 |
| institution | Redalyc |
| language | en |
| publishDate | 2020 |
| publisher | Universidad del Zulia |
| spellingShingle | Government-Use License and Stem Cell-Based Pharmaceuticals Patent: Equitable Access to Covid-19 Medications Mas RAHMAH Política 19 Covid drugs patent Indonesia Government-Use License and Stem Cell-Based Pharmaceuticals Patent: Equitable Access to Covid-19 Medications Mas RAHMAH Política 19 Covid drugs patent Indonesia In response to the outbreak of the Covid-19 pandemic, some pharmaceutical companies have patented their drugs to combat it, including those based on stem cells. Questions about how to access such drugs will likely be raised because patent protection grants an exclusive right to the patent owner, to prevent someone else from benefiting from a large-scale price increase. The document will then review the regulation and practice of government use in Indonesia and the possibility of such a mechanism to access Covid-19 drugs. 2020 artículo científico 1316-5216 https://www.redalyc.org/articulo.oa?id=27964362009 https://www.redalyc.org/journal/279/27964362009/ https://www.redalyc.org/journal/279/27964362009/html/ https://www.redalyc.org/journal/279/27964362009/27964362009.epub https://www.redalyc.org/journal/279/27964362009/movil https://doi.org/10.5281/zenodo.4009611 en http://www.redalyc.org/revista.oa?id=279 Utopía y Praxis Latinoamericana application/pdf Universidad del Zulia Utopía y Praxis Latinoamericana (República Bolivariana de Venezuela) Num.7 Vol.25 |
| title | Government-Use License and Stem Cell-Based Pharmaceuticals Patent: Equitable Access to Covid-19 Medications |
| topic | Política 19 Covid drugs patent Indonesia |
| url | https://www.redalyc.org/articulo.oa?id=27964362009 https://www.redalyc.org/journal/279/27964362009/ https://www.redalyc.org/journal/279/27964362009/html/ https://www.redalyc.org/journal/279/27964362009/27964362009.epub https://www.redalyc.org/journal/279/27964362009/movil https://doi.org/10.5281/zenodo.4009611 |